Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer. The company said Wednesday that Garg will help oversee an integrated R&D organization to ...

Ratings for Alnylam Pharmaceuticals ALNY -1.28% Get Free Report were provided by 18 analysts in the past three months, ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9 ...

Alnylam Pharmaceuticals, Inc. ALNY announced that the European Commission (EC) has approved a label expansion of its RNAi ...

Whoop’s illuminated logo looms over Fenway Park’s Green ... mum about Prasad’s recent contributions. In 2024, Alnylam launched a new RNAi therapy for a rare heart condition, reinforcing ...

AMVUTTRA® (vutrisiran) product logo ATTR-CM is a devastating ... Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Twenty-two years in and Alnylam Pharmaceuticals is still ...

− Proven Consistency of Effect on Cardiovascular Outcomes, Function, and Quality of Life in ATTR-CM Population Representative of Today’s Patients – – Only Therapeutic Approved in the U.S ...

CAMBRIDGE, Mass., March 20, 2025--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA ...

On Tuesday, Maraganore launched a start-up, City Therapeutics, that builds on his 20-year career at Alnylam by making smaller versions of the RNA molecules that silence genes to treat diseases.

Johnson cited Alnylam Pharmaceuticals, a Cambridge, Mass.-based RNAi therapeutics company ... marching in a Pride Parade and changing the company logo on LinkedIn during Pride Month in June. Jayson ...